LENSAR (LNSR) AI Stock Analysis

• Market Cap: $145.13M
• Dividend Yield: N/A
• Average Volume (3M): 42.04K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.71
• Revenue Growth: 21.02%
• EPS Growth: -200.88%
• Country: US
• Employees: 140
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.31
• Shares Outstanding: 11,934,784
• 10 Day Avg. Volume: 41,933
• 30 Day Avg. Volume: 42,039
• PEG Ratio: -0.03
• Price to Book (P/B): 21.18
• Price to Sales (P/S): 1.92
• P/FCF Ratio: -42.36
• Enterprise Value/Market Cap: 1.05
• Enterprise Value/Revenue: 2.59
• Enterprise Value/Gross Profit: 5.61
• Enterprise Value/Ebitda: -8.77
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: $10.00 ▼(-18.57% Downside)

LENSAR's overall stock score is driven by significant financial challenges, including persistent losses and negative margins. Technical analysis indicates bearish momentum, and valuation metrics are unfavorable with a negative P/E ratio. The lack of earnings call data and corporate events does not alter the negative outlook.

Positive Factors

Revenue Growth

The increase in revenue indicates growing adoption of LENSAR's products, suggesting a strengthening market position and potential for sustained growth.

Product Adoption

The expanding installed base of ALLY systems highlights successful market penetration and customer satisfaction, which can drive long-term revenue.

Strategic Acquisition

The acquisition by Alcon could enhance LENSAR's resources and market reach, providing strategic benefits and potential synergies for future growth.

Negative Factors

Negative Profit Margins

Persistent negative margins indicate ongoing operational inefficiencies, which could challenge LENSAR's ability to achieve profitability in the near term.

Solvency Issues

A negative equity position raises concerns about financial stability and limits the company's ability to leverage debt for growth initiatives.

Operating Cash Flow

Negative operating cash flow suggests challenges in generating sufficient cash from operations, potentially impacting liquidity and investment capacity.

LENSAR Business Overview & Revenue Model

Company Description

LENSAR, Inc. is a medical technology company specializing in advanced ophthalmic surgical solutions, primarily focused on cataract surgery. The company develops and markets the LENSAR Laser System, which utilizes precision laser technology to enhance the efficiency and accuracy of cataract procedures. By integrating digital imaging and advanced software, LENSAR aims to improve patient outcomes and streamline the surgical process for ophthalmic surgeons.

How the Company Makes Money

LENSAR generates revenue through the sale of its proprietary LENSAR Laser Systems and the associated consumables used during cataract surgeries, such as disposable tips and patient-specific software. The company also earns income from service contracts and maintenance agreements for its equipment. Significant partnerships with ophthalmic surgery centers and hospitals play a crucial role in expanding its market reach and driving sales. Additionally, LENSAR may benefit from reimbursements from insurance providers for procedures performed using its technology, enhancing its overall revenue potential.

LENSAR Financial Statement Overview

Summary

LENSAR's financial performance is weak, with consistent net losses and negative profit margins. The balance sheet shows negative stockholders' equity and potential solvency issues. Despite minor improvements in revenue and free cash flow growth, the overall financial health remains precarious.

Income Statement

LENSAR's income statement reveals a challenging financial position with consistent net losses and negative profit margins. The TTM data shows a slight revenue growth of 2.28%, but the company continues to struggle with high net loss margins of -84.49%. Gross profit margins have decreased slightly over the years, indicating pressure on profitability. The EBIT and EBITDA margins remain negative, highlighting ongoing operational challenges.

Balance Sheet

The balance sheet reflects a concerning financial structure with negative stockholders' equity in the TTM period, resulting in a negative debt-to-equity ratio. This indicates potential solvency issues. The return on equity is alarmingly high at 51.79% in the TTM, driven by negative equity, which is not sustainable. The equity ratio has deteriorated, suggesting increased financial risk.

Cash Flow

Cash flow analysis shows some positive trends, with free cash flow growth of 29.25% in the TTM. However, operating cash flow remains negative, and the operating cash flow to net income ratio is unfavorable at -0.17. The free cash flow to net income ratio is slightly positive, indicating some efficiency in cash management despite ongoing losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	59.14M	53.49M	42.16M	35.36M	34.46M	26.38M
Gross Profit	27.29M	25.85M	21.11M	19.95M	17.83M	14.07M
EBITDA	-17.44M	-3.00M	-8.71M	-16.77M	-16.89M	-15.36M
Net Income	-51.52M	-31.40M	-14.38M	-19.91M	-19.60M	-19.77M
Balance Sheet
Total Assets	70.20M	66.30M	69.58M	55.84M	66.47M	79.12M
Cash, Cash Equivalents and Short-Term Investments	16.87M	22.45M	24.06M	14.67M	31.64M	40.60M
Total Debt	2.88M	2.61M	2.31M	2.80M	3.31M	3.81M
Total Liabilities	82.33M	47.65M	22.41M	13.86M	11.59M	11.91M
Stockholders Equity	-25.91M	18.65M	47.18M	41.98M	54.88M	67.21M
Cash Flow
Free Cash Flow	-11.88M	-2.43M	-9.89M	-14.97M	-9.32M	-14.16M
Operating Cash Flow	-11.79M	-2.27M	-9.66M	-14.86M	-8.97M	-13.79M
Investing Cash Flow	-969.00K	-2.16M	-4.16M	-115.00K	-354.00K	-326.00K
Financing Cash Flow	9.96M	78.00K	19.76M	-1.99M	361.00K	50.00M

LENSAR Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 12.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LNSR, the sentiment is Negative. The current price of 12.28 is above the 20-day moving average (MA) of 11.96, above the 50-day MA of 12.14, and below the 200-day MA of 12.79, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 30.69 is Neutral, neither overbought nor oversold. The STOCH value of 29.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LNSR.

LENSAR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SGHT	58 Neutral	$260.79M	-5.19	-57.91%	―	-4.39%	11.70%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RPID	51 Neutral	$137.05M	―	-68.83%	―	16.63%	10.43%
HYPR	47 Neutral	$96.28M	-1.97	-77.26%	―	-9.59%	8.78%
RCEL	42 Neutral	$114.96M	―	-1746.27%	―	20.59%	18.61%
TELA	39 Underperform	$51.11M	-1.15	-676.41%	―	16.34%	34.86%
LNSR	38 Underperform	$145.13M	―	-422.35%	―	21.02%	-200.88%

LENSAR Corporate Events

LENSAR Reports Growth Amid Acquisition Developments

LENSAR, Inc. is a global medical technology company specializing in advanced robotic laser solutions for cataract treatment, known for its ALLY Robotic Cataract Laser System which integrates AI and dual-modality laser technology. In its third quarter of 2025, LENSAR reported a 6% increase in revenue compared to the same period in 2024, driven by an 11% rise in worldwide procedure volume and a significant expansion of its ALLY Systems installed base. The company placed 18 new ALLY Systems, marking a 77% increase in its installed base over the previous year. Despite these gains, LENSAR faced a net loss of $3.7 million, largely attributed to acquisition-related expenses from its pending merger with Alcon. The company’s cash reserves decreased by $3.4 million during the quarter, leaving a balance of $16.9 million. Looking ahead, LENSAR remains focused on completing its acquisition by Alcon, expected in early 2026, while continuing to enhance its product offerings and operational efficiencies.

LENSAR Announces Virtual Annual Meeting Plans

LENSAR, Inc. has announced that its 2025 annual meeting of stockholders is scheduled for December 18, 2025, to be held virtually. This meeting will only occur if the proposed merger with Alcon Research, LLC is not completed before the meeting date. If the merger is completed, LENSAR will become a wholly owned subsidiary of Alcon, and the meeting will not take place. Stockholders are advised of revised deadlines for submitting proposals and nominations, which must be received by October 31, 2025.

The most recent analyst rating on (LNSR) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on LENSAR stock, see the LNSR Stock Forecast page.

Lensar Inc. Reports Growth Amid Merger Progress

Lensar Inc., a global medical technology company, specializes in advanced robotic laser solutions for cataract treatment and astigmatism management. The company recently reported its financial results for the second quarter of 2025, highlighting significant growth in its ALLY Robotic Cataract Laser Systems and an ongoing merger with Alcon. During the second quarter of 2025, Lensar achieved a total revenue of $13.9 million, marking a 10% increase from the previous year, driven by a 23% rise in worldwide procedure volumes. The company also placed 18 new ALLY Systems, expanding its installed base by 107% compared to the previous year. Despite a net loss of $1.8 million, Lensar’s financial performance improved significantly from the $9.0 million loss in the same quarter of 2024, largely due to changes in warrant liabilities. Looking ahead, Lensar’s management remains optimistic about the proposed merger with Alcon, expecting it to close by the end of the year, which could potentially transform the company’s operational landscape.